Fe Pharmaceuticals

07/23/2024

Big patent and team news today: our 3rd US patent on DIBI issued this month and Dr. Trisha Ang joined our team as VP of Research and Development. She is very experienced with DIBI having synthesized it and leading the manufacturing process optimization and being a co-inventor on this and other DIBI patents.

July 23, 2024, Redwood City, CA, USA – Fe Pharmaceuticals, a pioneering biotech company focused on innovative treatments for infectious diseases, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,024,490, titled "Polymeric Metal Chelati...

11/14/2023

Proud to join other exciting Canadian Life Science startups in Silicon Valley this week.

10/04/2023

Must watch film. What we are working to overcome at Fe Pharmaceuticals. Our product DIBI kills infections without antibiotics, synergizes with antibiotics, and protects antibiotics from emerging resistance.

From Tori, a college gymnast, who faced a once curable infection that escalated into a life-threatening crisis, to Kerry, battling relentless superbugs with ...

09/08/2023

Making the most of the World AMR Congress. Hundreds of professionals dedicated to combatting antimicrobial resistance, giving voice to the silent pandemic. Andrew Heaton, COO and Michael Weickert, CEO Fe Pharmaceuticals, Philadelphia, PA.

08/31/2023

Headed to World AMR Congress next week in Phili (Sept. 7-8). Antimicrobial resistance has a solution: DIBI, our antimicrobial polymer that is immune to resistance and when administered alongside an antibiotic, prevents resistance from emerging to the antibiotic as well. Come by and see our poster of results.

06/13/2023

Fe Pharmaceuticals is pleased to announce the appointment of Dr. Anne-Marie Duliege as Chair of the Board of Directors. She brings outstanding clinical leadership experience as Fe works towards entering clinical studies.

June 12, 2023, Redwood City, CA, USA- Fe Pharmaceuticals (Canada) and its US subsidiary, Fe Pharmaceuticals, announced today that Anne-Marie Duliege, has been elected as Chairperson of the Board of Directors of the company. CEO Michael Weickert relinquished that role to focus on financing the develo...

04/25/2023

We are delighted to announce that Fe Pharmaceuticals closed a SEED Investment and named Robert Klein to the Board of Directors. Bob Klein, the father of CIRM, the California Stem cell initiative, led the round and will be a Senior Advisor to the Board of Fe. Their interest is addressing major public health threats with new technologies and we could not be more excited to have them on our team.

April 25, 2023, Redwood City, CA, USA- Fe Pharmaceuticals has raised a SEED investment to continue developing DIBI, a non-toxic, iron-binding copolymer, as a potent, broad-spectrum, antimicrobial agent active against bacterial and fungal infections, including drug-resistant organisms and as a potent...

02/06/2023

Canada in the Valley Showcase - Participating Startup Spotlight Series

Genuine breakthroughs in infectious disease are rare but this is one. Fe Pharmaceuticals is developing DIBI, a non-toxic, iron-binding copolymer, as a potent (

11/19/2022

Today starts World Antimicrobial Awareness Week (18-24 November 2022). Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat. Researchers estimated that AMR in bacteria caused an estimated 1.27 million deaths in 2019. Fe Pharmaceuticals just published research that showed the drug DIBI inhibits the formation of resistance to antibiotics when co-administered with antibiotics - a potential solution to this major and growing problem.

World Antimicrobial Awareness Week aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices.

11/18/2022

Fe Pharmaceuticals just published data supporting showing that DIBI, in combination treatment with antibiotics, can suppress resistance to antibiotics. This is a major breakthrough for treating infections because fear of resistance is a major limitation.

Antibiotic resistance of bacterial pathogens results from their exposure to antibiotics and this has become a serious growing problem that limits effective use of antibiotics. Resistance can arise from mutations induced by antibiotic-mediated damage with these mutants possessing reduced target sensi...

08/19/2022

Fe Pharmaceuticals will present at the upcoming World AMR Congress, September 7-8, 2022, near Washington DC. The poster entitled: "Iron withholding by DIBI sensitizes antibiotic resistant pathogens to diverse antibiotic classes in vitro and in vivo" will be available both days and the company's CEO, Michael Weickert, PhD, will be in attendance. Fe Pharmaceuticals is developing an extraordinarily innovative approach to infections, starving them for iron, which has been demonstrated in 27 published studies and is immune to development of resistance as well as synergistic with existing anti-infective agents. We look forward to engaging stakeholders with our unique solution. , , , ,

10/29/2021

Kicked off CELS Valley ready program with great cohort of Canadian Biotech companies: https://cels-sfo.com/page-18139

The CELS Valley Ready (VR) program is a comprehensive series of activities that coaches, promotes and connects its participating Canadian Life Science Companies to achieve their objectives in the Silicon Valley.

10/05/2021

Honored to be part of this event and looking forward to meeting with potential partners and investors this week.

09/18/2021

Fe Pharmaceuticals is trying to meet extraordinary medical needs. The stakes are enormous if we can’t control infections:

09/18/2021

New Name! New website! US subsidiary! Fe Pharmaceuticals launches! https://fepharm.com/fe-pharmaceuticals-launches-us-subsidiary-names-new-independent-board-members/

Fe Pharmaceuticals Launches US Subsidiary, Names New Independent Board Members  September 23, 2020, Halifax, Nova Scotia, Canada Fe Pharmaceuticals (Canada) has created a new US subsidiary, Fe Pharmaceuticals, to develop DIBI, a non-toxic, iron-binding copolymer, as a potent, broad-spectrum, anti...

09/17/2021

03/19/2021

Nice cover (our Executive Chairman); Chelation Partners is inside!

03/19/2021

Our Executive Chairman profiled in CIO Views describing Life Science Diamonds in the Rough, including Chelation Partners. https://cioviews.com/life-science-diamonds-in-the-rough/

There is a perception that medical advances are mostly made incrementally through years of toil in laboratories and clinics with only occasional breakthroughs changing care dramatically. Nothing reinforces that impression more than the recent striking success of mRNA vaccines in preventing COVID-19....

03/01/2021

Chelation Partners was named an Impact startup for the Global technology Collision Conference, April 20-22, 2021. Collision is a massive annual startup conference and Impact startups are those with one or more of the following:
1. pursuing one or more of the UN Sustainable Development Goals in operations.
2. adjusting and adapting enterprise objectives to be more sustainable.
3. solving problems in your industry that could have a far-reaching effect.
4. prioritizing social collaboration over competition.

Chelation Partners is also a featured startup in MedTech and Pharma.

02/25/2021

We definitively showed that DIBI, our non toxic iron binding polymer, is superior to approved iron chelators in animal models of sepsis. Peritoneal infection burden was reduced 10-fold by DIBI while DFX and DFP provided no reductions. Overall, the results, together with those from other studies, revealed serious
limitations for each of the three hematological chelators, i.e., as potentially repurposed for treating infection/sepsis. In contrast, DIBI provided therapeutic benefits, consistent with various in vitro and in vivo results from other studies, supporting the potential for its use in treating sepsis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830599/